John Renger - 15 Dec 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Dec 2021
Net transactions value: -$1,031,248
Form type: 4
Filing time: 17 Dec 2021, 19:27:33 UTC
Previous filing: 15 Nov 2021
Next filing: 23 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$87,500	+25,000	+1263%	$3.50^*	26,980	15 Dec 2021	Direct	F1, F2
transaction	CERE	Common Stock	Sale	$750,448	-25,000	-93%	$30.02	1,980	15 Dec 2021	Direct	F1, F3
transaction	CERE	Common Stock	Options Exercise	$19,523	+5,578	+282%	$3.50^*	7,558	16 Dec 2021	Direct	F1
transaction	CERE	Common Stock	Sale	$181,285	-5,578	-74%	$32.50	1,980	16 Dec 2021	Direct	F1
transaction	CERE	Common Stock	Options Exercise	$24,927	+7,122	+360%	$3.50^*	9,102	17 Dec 2021	Direct	F1
transaction	CERE	Common Stock	Sale	$231,465	-7,122	-78%	$32.50	1,980	17 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-25,000	-5.9%	$0.000000	400,875	15 Dec 2021	Common Stock	25,000	$3.50	Direct	F1, F4
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-5,578	-1.4%	$0.000000	395,297	16 Dec 2021	Common Stock	5,578	$3.50	Direct	F1, F4
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-7,122	-1.8%	$0.000000	388,175	17 Dec 2017	Common Stock	7,122	$3.50	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021.
F3	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.